Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC
NCT04952168Phase 2Unknown
- Start
- Jun 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of almonertinib in non-small cell lung cancer (NSCLC). Status: unknown.
02
Drugs
almonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04952168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952168.